Atai stocks.

ATAI Life Sciences is a biopharmaceutical company focused on developing psychedelic-based treatments for mental health conditions. The company has a diverse …ATAI Life Sciences NV (ATAI) stock is lower by -5.5% while the S&P 500 has risen 0.05% as of 9:55 AM on Thursday, Oct 19. ATAI has fallen -$0.07 from the previous closing price of $1.36 on volume of 137,605 shares. Over the past year the S&P 500 has gained 16.04% while ATAI has fallen -54.42%. ATAI lost -$0.92 per share in the over the last 12 ...Discover historical prices for ATAI stock on Yahoo Finance. View daily, weekly or monthly format back to when Atai Life Sciences N.V. stock was issued. Mar 31, 2023 · Atai Life Sciences ( ATAI 2.80%), a small-cap drugmaker developing psychedelic-based treatments for drug dependency and mental health disorders, posted strong gains during the first four days of ...

ATAI Life Sciences is a biopharmaceutical company focused on developing psychedelic-based treatments for mental health conditions. The company has a diverse portfolio of drug candidates in various ...

The sector offers explosive growth potential, evidenced by the recent positive coverage of psychedelic stocks by investment research firms like Citi, Credit Suisse, Canaccord Genuity, and Cantor ...35,390.15 +117.12(+0.33%) Nasdaq -15.00(-0.11%) Russell 2000 1,807.50 +11.96(+0.67%) Crude Oil 75.54 -1.56(-2.02%) Gold 2,003.00 +10.20(+0.51%) Atai Life Sciences N.V. (ATAI) NasdaqGM -...

The stock has given up three-quarters of its market value year to date. Ark Genomic bought 67,384 shares of Atai Life Sciences - Get Free Report, valued at $284,360. Atai is a Berlin ...Atai Life Sciences (NASDAQ:ATAI) said its majority-owned unit Perception Neuroscience's therapy PCN-101 (R-ketamine) did not meet the main goal of a phase 2a trial for treatment-resistant depression.Get the latest Butterfly Network Inc (BFLY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.WebStock analysis for ATAI Life Sciences NV (ATAI:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

The current price ATAI Life Sciences (ATAI) is trading at is $1.06, which is within the analyst’s predicted range. Browse analyst ratings and price targets on all stocks. Popular Channels

Even in a speculative industry, I believe the stock is undervalued by these few facts alone. ATAI holds: 450M cash and cash equivalents; 20% equity stake in CMPS (750M mktcp - 150M worth at current prices); and ATAI has a vast ip pipeline that includes 9 lead compounds. Curious as to the community’s thoughts here!

Stock Price Forecast ... The 5 analysts offering 12-month price forecasts for ATAI Life Sciences NV have a median target of 11.00, with a high estimate of 21.00 ...Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.ATAI Stock 12 Months Forecast. $14.00. (960.61% Upside) Based on 4 Wall Street analysts offering 12 month price targets for ATAI Life Sciences in the last 3 months. The average price target is $14.00 with a high forecast of $20.00 and a low forecast of $11.00. The average price target represents a 960.61% change from the last price of $1.32.The Atai Life Sciences N.V. stock forecast for tomorrow is $ 1.055893, which would represent a -2.23% loss compared to the current price. In the next week, the price of ATAI is expected to decrease by -18.90% and hit $ 0.875911. As far as the long-term Atai Life Sciences N.V. stock forecast is ...Aug 30, 2022 · ATAI stock is down 44% year-to-date (YTD), despite a 10% increase over the past month. Shares are changing hands at 2.4x book value. Wall Street’s 12-month median price forecast for ATAI stock ...

Mar 6, 2023 · In January, Atai's majority-owned unit Perception Neuroscience's therapy PCN-101 (R-ketamine) did not meet the main goal of a phase 2a trial in treatment-resistant depression which sent the stock ... ATAI Life Sciences N.V. analyst ratings, historical stock prices, earnings estimates & actuals. ATAI updated stock price target summary. The latest atai Life Sciences stock prices, stock quotes, news, and history to help you invest and trade smarter.Nov 29, 2023 · ATAI Life Sciences is a biopharmaceutical company focused on developing psychedelic-based treatments for mental health conditions. The company has a diverse portfolio of drug candidates in various ... The current price ATAI Life Sciences (ATAI) is trading at is $1.06, which is within the analyst’s predicted range. Browse analyst ratings and price targets on all stocks. Popular ChannelsN/A. 1. Capital is getting (a lot) harder to come by. Perhaps the most frustrating trend for investors considering psychedelic stocks is the rising cost of borrowing money. As inflation surges in ...Nov 29, 2023 · ATAI Life Sciences is a biopharmaceutical company focused on developing psychedelic-based treatments for mental health conditions. The company has a diverse portfolio of drug candidates in various ...

Data sources: Yahoo! Finance and company websites. Market caps as of Oct. 23, 2023. Company Market Cap Description Atai Life Sciences (NASDAQ:ATAI) $215.8 millionMar 31, 2023 · The stock had already been climbing after its fourth-quarter and full-year report was released on March 24, but a spate of inside buying on Wednesday by Atai co-founder and chairman Christian ...

Nov 14, 2023 · Clinical-stage psychedelics company atai Life Sciences (NASDAQ: ATAI) reported its financial results and corporate updates for the third quarter ended September 30, 2023. In numbers: Find real-time ATAI - ATAI Life Sciences NV stock quotes, company profile, news and forecasts from CNN Business.The upgrade of atai Life Sciences N.V. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the ...Funding. ATAI Life Sciences has raised a total of. $522.1M. in funding over 11 rounds. Their latest funding was raised on Aug 15, 2022 from a Post-IPO Debt round. ATAI Life Sciences is registered under the ticker NASDAQ:ATAI . Their stock opened with $15.00 in its Jun 17, 2021 IPO. ATAI Life Sciences is funded by 42 investors.WebFind real-time SMCI - Super Micro Computer Inc stock quotes, company profile, news and forecasts from CNN Business.WebATAI Life Sciences is a biopharmaceutical company focused on developing psychedelic-based treatments for mental health conditions. The company has a diverse portfolio of drug candidates in various ...In May 2021, Atai purchased additional preferred stock of Neuronasal. As of the date, the company now holds a 56.5% equity ownership position in Neuronasal – a company focused on treating concussions and other forms of …Aug 30, 2022 · ATAI stock is down 44% year-to-date (YTD), despite a 10% increase over the past month. Shares are changing hands at 2.4x book value. Wall Street’s 12-month median price forecast for ATAI stock ...

Nov 30, 2023 · ATAI Life Sciences NV’s trailing 12-month revenue is $0.3 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-0.317 per share for the current fiscal year. ATAI Life Sciences NV does not currently pay a dividend.

Mar 7, 2023 · According to 6 analyst offering 12-month price targets in the last 3 months, ATAI Life Sciences has an average price target of $15.33 with a high of $23.00 and a low of $9.00. Below is a summary ...

Find real-time ATAI - ATAI Life Sciences NV stock quotes, company profile, news and forecasts from CNN Business.Mar 27, 2023 · 0. These 7 analysts have an average price target of $13.29 versus the current price of ATAI Life Sciences at $1.3447, implying upside. Below is a summary of how these 7 analysts rated ATAI Life ... atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Headquartered in Berlin, with offices in New York and London, our vision is to heal mental health disorders so that everyone everywhere can live a more fulfilled life. Nov 29, 2023 · The average trading volume of ATAI on November 29, 2023 was 536.92K shares. ATAI) stock’s latest price update. The stock price of ATAI Life Sciences N.V. (NASDAQ: ATAI) has plunged by -3.51 when compared to previous closing price of 1.14, but the company has seen a 2.80% gain in its stock price over the last five trading sessions. IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle.WebHow many ATAI shares are owned by institutional investors? 24.8M ATAI shares ... Trading stocks, options and other securities involves risk. The risk of loss ...If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Psychedelic Stocks to Buy Now. ... CMPS), Atai Life Sciences N.V. (NASDAQ: ATAI), and Seelos Therapeutics, Inc ...Can ATAI Life Sciences N.V. (NASDAQ: ATAI) Still Be Considered A Loss When It’s Down -57.89% YTD? Marketing Sentinel about 20 hours ago ATAI Life Sciences NV Reports Qâ â â ¦â â Financial Results and Pipeline Progress GuruFocus 16 days ago Atai Life Sciences' Q3 Earnings: Near $20M Burned QoQ, Says Funding 'Sufficient' To Streamline 2026 …WebNov 17, 2023 · The upgrade of atai Life Sciences N.V. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the ... Dec 1, 2023 · See the latest ATAI Life Sciences NV stock price (ATAI:XNAS), related news, valuation, dividends and more to help you make your investing decisions. On December 2, 2023, the Board appointed Sahil Kirpekar, M.D. and Ryan Barrett as the new atai Board designees pursuant to the Rights Agreement, to serve until the 2024 annual meeting of the ...Webatai Life Sciences N.V. - Buy. Zacks' proprietary data indicates that atai Life Sciences N.V. is currently rated as a Zacks Rank 2 and we are expecting an above average return from the ATAI shares ...

At Compass’ current market cap of ~$1.1 billion, ATAI has a $200 – 300 million stake in the company. This gives ATAI’s valuation a sort of floor dependent on Compass’ ultimate market cap. It will be just as important for Compass to succeed over the coming months as it will for ATAI’s portfolio companies to perform.WebFrom July 5 to July 7, the ARK Genomic Revolution ETF purchased 268,974 shares of ATAI Life Sciences (NASDAQ: ATAI). This was the ETF and Ark Invest’s first purchase of ATAI stock since March 14.After declining more than 62% over the past six months, ATAI stock needs a positive catalyst to turn things around. This is likely part of the reason behind the Atai layoffs, which follow the company’s promise to implement a “company-wide cost optimization” initiative, a measure that hasn’t yet yielded the intended results.WebATAI Stock 12 Months Forecast. $14.00. (960.61% Upside) Based on 4 Wall Street analysts offering 12 month price targets for ATAI Life Sciences in the last 3 months. The average price target is $14.00 with a high forecast of $20.00 and a low forecast of $11.00. The average price target represents a 960.61% change from the last price of $1.32.Instagram:https://instagram. top financial group stocksregional stockddd stock forecast6 month tbill rates 377.43. -0.11%. 9.38M. View today's Atari stock price and latest ALATA news and analysis. Create real-time notifications to follow any changes in the live stock price.WebNov 30, 2023 · ATAI Life Sciences NV’s trailing 12-month revenue is $0.3 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-0.317 per share for the current fiscal year. ATAI Life Sciences NV does not currently pay a dividend. tax software for independent contractorswalker and dunlop stock ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian …ATAI is down -$0.02 from the previous closing price of $1.14 on volume of 308,405 shares. Over the past year the S&P 500 has risen 15.21% while ATAI is down -62.79%. ATAI lost -$0.46 per share in the over the last 12 months. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ... investing in cash app The Atai Life Sciences N.V. stock forecast for tomorrow is $ 1.095019, which would represent a -2.23% loss compared to the current price. In the next week, the ...Beam Therapeutics Inc. (BEAM) The first Wood-backed stock we’ll look at is Beam Therapeutics, a pioneer in the application of base editing. This is a potentially new class of precision genetic ...Web